Sonoma Pharmaceuticals, Inc.Find Ratings Reports
SONOMA PHARMACEUTICALS INC's gross profit margin for the fourth quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its subsector. SONOMA PHARMACEUTICALS INC has strong liquidity. Currently, the Quick Ratio is 1.72 which shows the ability to cover short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 38.39% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY20||Q4 FY19|
|Net Sales ($mil)||2.16||4.31|
|Net Income ($mil)||-3.66||-1.74|
|Balance Sheet||Q4 FY20||Q4 FY19|
|Cash & Equiv. ($mil)||4.22||3.69|
|Total Assets ($mil)||14.99||14.56|
|Total Debt ($mil)||2.68||1.48|
|Profitability||Q4 FY20||Q4 FY19|
|Gross Profit Margin||-7.14||34.25|
|Return on Assets||-26.35||-22.71|
|Return on Equity||-86.05||-41.05|
|Debt||Q4 FY20||Q4 FY19|
|Share Data||Q4 FY20||Q4 FY19|
|Shares outstanding (mil)||2.09||1.78|
|Div / share||0.0||0.0|
|Book value / share||2.56||4.9|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||62747.0||301699.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 2.47 indicates a significant discount versus the S&P 500 average of 4.54 and a significant discount versus the subsector average of 10.83. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, SONOMA PHARMACEUTICALS INC proves to trade at a discount to investment alternatives.
|SNOA NM||Peers 28.65||SNOA NM||Peers 20.01|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SNOA's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SNOA's P/CF is negative making the measure meaningless.
|SNOA NA||Peers 16.37||SNOA NA||Peers 0.51|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SNOA 2.47||Peers 10.83||SNOA -0.44||Peers -60.49|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SNOA is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
SNOA is expected to have an earnings growth rate that significantly exceeds its peers.
|SNOA 0.71||Peers 28.96||SNOA 3.91||Peers 25.90|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SNOA is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
SNOA significantly trails its peers on the basis of sales growth.